Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Telmisartan + Amlodipine

Small molecule

Daewon Pharmaceutical Co., Ltd.

0

Indications

3

Total Trials

0

Active Trials

0

Competitors

2

FDA Applications

NDA/BLA/ANDA regulatory filings

Clinical

Trials by Indication[1]

Hypertension1 trial

Evaluate the Efficacy and Safety of Combination Treatment With DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients With Hypertension and Dyslipidemia

Completed· Daewon Pharmaceutical Co., Ltd. logo

Daewon Pharmaceutical Co., Ltd.·Phase 3·NCT03210532·129 enrolled

Metabolic Syndrome1 trial

A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic Syndrome

Terminated·YYuhan Corporation·Phase 4·NCT02968160·55 enrolled

Trial1 trial

Add-on to Micamlo BP Trial

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT01975246·309 enrolled

Regulatory

FDA Approval Timeline[3]

Jun 5, 2025

WIDAPLIK

NDA NDA219423

May 28, 2026

WIDAPLIK

NDA NDA219423

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Telmisartan + Amlodipine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Telmisartan + Amlodipine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA219423). U.S. Food & Drug Administration.
[4]
SEC EDGAR — Daewon Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: Daewon Pharmaceutical Co., Ltd.

Related News